Currently, long-term cure is achieved in only 60% of pediatric AML cases and the possibility of relapse is still high, ranging between 25% and 35% [2], especially for poor prognosis AML subtypes including FMS-like tyrosine kinase 3 (FLT3) mutated and mixed lineage leukemia rearranged (MLL-r). This evidence concerns the gene KMT2A and acute myeloid leukemia.